Conformationally restricted carbamate inhibitors of horse serum butyrylcholinesterase.

This article investigates a set of structurally constrained carbamate inhibitors’ ability to irreversibly inhibit a specific enzyme found in horse serum, highlighting Compound 1 as the most effective inhibitor.

Research Overview

• This research paper focuses on the study of four type of carbamate inhibitors, specifically, exo-2-norbornyl-N-butylcarbamate (1), endo-2-norbornyl-N-butylcarbamate (2), l-adamantyl-N-butylcarbamate (3), and 2-adamantyl-N-butylcarbamate (4).
• These compounds were studied as active site-directed irreversible inhibitors of butyrylcholinesterase, an enzyme typically found in horse serum.
• The effectiveness of the inhibitors was measured using a number of constants namely, the dissociation constant (KI), the carbamylation constant (k2), and the bimolecular rate constant (ki).

Key Findings

• Among the compounds studied, Compound 1 (exo-2-norbornyl-N-butylcarbamate) was found to be the most potent inhibitor of the butyrylcholinesterase enzyme.
• The effectiveness of this compound was characterized by its dissociation constant (KI) being 20 nM and its bimolecular rate constant (ki) being 1.1 x 10(5) M-1sec-1.
• This suggests that compound 1 has a high affinity for the enzyme, efficiently binding to it and successfully preventing the enzyme from functioning as it normally would.

Significance

• This research provides insights into the development of efficient enzyme inhibitors. It highlights the importance of structural considerations when designing inhibitors, showcasing the effectiveness of conformationally restricted carbamate inhibitors.
• Such inhibitors can have a wide range of applications, including but not limited to, therapeutic interventions and research tools to understand enzyme functions better.
• The inhibitors may also find uses within veterinary science, given their effectiveness on horse serum enzyme in this study.